Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
An Umbrella, Randomized, Controlled, Pre Operative Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer
Sponsor: Effector Therapeutics
A PHASE2 clinical study on Breast Cancer and ER Positive Breast Cancer, this trial is completed. The trial is conducted by Effector Therapeutics and has accumulated 12 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
Status: Suspended → Completed
-
Aug 2025 — Feb 2026 [monthly]
Suspended PHASE2
Status: Active Not Recruiting → Suspended
-
Sep 2024 — Aug 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Apr 2023 — May 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2022 — Mar 2023 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2022 — Dec 2022 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Effector Therapeutics
- Jennifer Lee Caswell-Jin
- Novartis Pharmaceuticals
- United States Department of Defense
For direct contact, visit the study record on ClinicalTrials.gov .